Prior Balloon Valvuloplasty Versus Direct Transcatheter Aortic Valve Replacement: Results From the DIRECTAVI Trial

• Published in: JACC. Cardiovascular interventions Vol. 13; no. 5; p. 594
• Main Authors: Leclercq, Florence, Robert, Pierre, Akodad, Mariama, Macia, Jean-Christophe, Gandet, Thomas, Delseny, Delphine, Chettouh, Marine, Schmutz, Laurent, Robert, Gabriel, Levy, Gilles, Targosz, Frederic, Maupas, Eric, Roubille, Francois, Marin, Gregory, Nagot, Nicolas, Albat, Bernard, Lattuca, Benoit, Cayla, Guillaume
• Format: Journal Article
• Language: English
• Published: United States 09.03.2020
• Subjects: transcatheter aortic valve replacement; randomized clinical trial; balloon aortic valvuloplasty; device success; direct implantation
• ISSN: 1876-7605
• DOI: 10.1016/j.jcin.2019.12.006

The aim of this study was to evaluate device success of transcatheter aortic valve replacement (TAVR) using new-generation balloon-expandable prostheses with or without balloon aortic valvuloplasty (BAV). Randomized studies are lacking comparing TAVR without BAV against the conventional technique of TAVR with BAV. DIRECTAVI (Direct Transcatheter Aortic Valve Implantation) was an open-label noninferiority study that randomized patients undergoing TAVR using the Edwards SAPIEN 3 valve with or without prior balloon valvuloplasty. The primary endpoint was the device success rate according to Valve Academic Research Consortium-2 criteria, which was evaluated using a 7% noninferiority margin. The secondary endpoint included procedural and 30-day adverse events. Device success was recorded for 184 of 236 included patients (78.0%). The rate of device success in the direct implantation group (n = 97 [80.2%]) was noninferior to that in the BAV group (n = 87 [75.7%]) (mean difference 4.5%; 95% confidence interval: -4.4% to 13.4%; p = 0.02 for noninferiority). No severe prosthesis-patient mismatch or severe aortic regurgitation occurred in any group. In the direct implantation group, 7 patients (5.8%) required BAV to cross the valve. Adverse events were related mainly to pacemaker implantation (20.9% in the BAV group vs. 19.0% in the direct implantation group; p = 0.70). No significant difference was found between the 2 strategies in duration of procedure, contrast volume, radiation exposure, or rate of post-dilatation. Direct TAVR without prior BAV was noninferior to the conventional strategy using BAV with new-generation balloon-expandable valves, but without procedural simplification. BAV was needed to cross the valve in a few patients, suggesting a need for upstream selection on the basis of patient anatomy. (TAVI Without Balloon Predilatation [of the Aortic Valve] SAPIEN 3 [DIRECTAVI]; NCT02729519).